School of Systems Biomedical Science, Soongsil University, Seoul, Republic of Korea.
AzothBio, Rm. DA724 Hyundai Knowledge Industry Center, Hanam-si, Gyeonggi-do, Republic of Korea.
Brief Bioinform. 2023 Sep 22;24(6). doi: 10.1093/bib/bbad396.
Kinases play a vital role in regulating essential cellular processes, including cell cycle progression, growth, apoptosis, and metabolism, by catalyzing the transfer of phosphate groups from adenosing triphosphate to substrates. Their dysregulation has been closely associated with numerous diseases, including cancer development, making them attractive targets for drug discovery. However, accurately predicting the binding affinity between chemical compounds and kinase targets remains challenging due to the highly conserved structural similarities across the kinome. To address this limitation, we present KinScan, a novel computational approach that leverages large-scale bioactivity data and integrates the Multi-Scale Context Aware Transformer framework to construct a virtual profiling model encompassing 391 protein kinases. The developed model demonstrates exceptional prediction capability, distinguishing between kinases by utilizing structurally aligned kinase binding site features derived from multiple sequence alignment for fast and accurate predictions. Through extensive validation and benchmarking, KinScan demonstrated its robust predictive power and generalizability for large-scale kinome-wide profiling and selectivity, uncovering associations with specific diseases and providing valuable insights into kinase activity profiles of compounds. Furthermore, we deployed a web platform for end-to-end profiling and selectivity analysis, accessible at https://kinscan.drugonix.com/softwares/kinscan.
激酶在调节细胞周期进程、生长、凋亡和代谢等基本细胞过程中起着至关重要的作用,其通过催化三磷酸腺苷(adenosing triphosphate)上的磷酸基团向底物的转移来实现。它们的失调与许多疾病密切相关,包括癌症的发生,这使得它们成为药物发现的有吸引力的靶点。然而,由于激酶家族中高度保守的结构相似性,准确预测化合物与激酶靶标的结合亲和力仍然具有挑战性。为了解决这个限制,我们提出了 KinScan,这是一种利用大规模生物活性数据并集成多尺度上下文感知转换器框架的新型计算方法,构建了一个包含 391 种蛋白激酶的虚拟分析模型。所开发的模型具有出色的预测能力,通过利用源自多序列比对的结构对齐激酶结合位点特征来区分激酶,实现快速而准确的预测。通过广泛的验证和基准测试,KinScan 展示了其强大的预测能力和在大规模激酶组范围内的通用性和选择性,揭示了与特定疾病的关联,并为化合物的激酶活性特征提供了有价值的见解。此外,我们部署了一个端到端分析和选择性分析的网络平台,可在 https://kinscan.drugonix.com/softwares/kinscan 访问。